Peking Union Medical College is the lead sponsor of 14 current clinical trials in our China register. 8 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Pyrotinib, Secukinumab and Abiraterone. The most-studied condition is Hidradenitis Suppurativa (HS).
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC
NCT07247227 · ClinicalTrials.gov ↗ · NSCLC
|
Not applicable | Recruiting | 2023-10 | China |
|
Effect of Hypophosphatemia on Neuro-excursion Efficiency During Mechanical Ventilator Weaning
NCT06754670 · ClinicalTrials.gov ↗ · Mechanical Ventilation, Weaning Failure, Hypophosphatemia
|
Observational | Recruiting | 2024-10 | China |
|
Tooth and Bone-borne Cutting/Repositioning Guide and Patient-specific Implant(PSI)
NCT07634276 · ClinicalTrials.gov ↗ · CAD/CAM, Patient Specific Implant, Orthognathic Surgery
|
Not applicable | Recruiting | 2026-06 | China |
|
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
NCT06145308 · ClinicalTrials.gov ↗ · Salivary Gland Carcinoma, Precision Therapy
|
Phase 2 | Recruiting | 2023-08 | China |
|
Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa
NCT07109765 · ClinicalTrials.gov ↗ · Hidradenitis Suppurativa (HS)
Drug: Secukinumab |
Observational | Recruiting | 2025-06 | China |
|
Nutrition Support on Outcomes and Cost-effectiveness for Patients at Risk
NCT00289380 · ClinicalTrials.gov ↗ · Malnutrition, Nutritional Risk
|
Observational | Recruiting | 2005-01 | China |
|
Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa
NCT06926192 · ClinicalTrials.gov ↗ · Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa), Secukinumab
|
Observational | Recruiting | 2020-01 | China |
|
Treatment for "Asymmetric Crying Facies"
NCT07802639 · ClinicalTrials.gov ↗ · Hemifacial Microsomia, Facial Nerve Paralysis
|
Not applicable | Recruiting | 2026-08 | China |
|
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
NCT04736589 · ClinicalTrials.gov ↗ · Breast Cancer
|
Phase 3 | Not yet open | 2021-02 | China |
|
Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS
NCT07261072 · ClinicalTrials.gov ↗ · Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa), Secukinumab
Drug: Secukinumab |
Phase 4 | Not yet open | 2025-12 | China |
|
Nutritional Support on Outcomes and Cost-effectiveness for Patients at Risk
NCT05917418 · ClinicalTrials.gov ↗ · Malnutrition
|
Not applicable | Not yet open | 2026-12 | China |
|
Exploratory Trial of VR Intervention on Neuroplasticity in Older Adults With Cognitive Frailty
NCT07183033 · ClinicalTrials.gov ↗ · Cognitive Frailty
|
Not applicable | By invitation | 2025-07 | China |
|
Critical Closing Pressure and PCO₂ Gap in Fluid Resuscitation for Septic Shock
NCT07043192 · ClinicalTrials.gov ↗ · Septic Shock, Fluid Resuscitation, Tissue Perfusion Pressure
|
Observational | Active, closed | 2025-04 | China |
|
A 24-Week Real-World Study of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa
NCT07727889 · ClinicalTrials.gov ↗ · Hidradenitis Suppurativa (Acne Inversa)
|
Phase 2 | Active, closed | 2026-07 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 14 | 8 |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| Oruka Therapeutics | 1 |
| Sonoma Biotherapeutics | 1 |
Sponsors with the most current trials registered for this condition.
Peking Union Medical College is the lead sponsor of 14 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 8 of its 14 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 23 drugs and biologicals as interventions. The most frequent are Pyrotinib (2), Secukinumab (2), Abiraterone (1), Albumin paclitaxel (1) and Albumin-Bound Paclitaxel (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.